Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability

Author:

Iannone Florenzo,Sinigaglia Lugi,Favalli Ennio Giulio,Sarzi-Puttini Piercarlo,Atzeni Fabiola,Caporali Roberto,Codullo Veronica,Ferraccioli Gianfranco,Gremese Elisa,Carletto Antonio,Giollo Alessandro,Govoni Marcello,Bergossi Francesca,Galeazzi Mauro,Cantarini Luca,Salaffi Fausto,Di Carlo Marco,Bazzani Chiara,Pellerito Raffaele,Sebastiani Marco,Ramonda Roberta,Lapadula Giovanni

Funder

AbbVie srl

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Reference22 articles.

1. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP (2013) Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis 72:517–524

2. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG (2006) Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65:753–759

3. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37

4. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–1474

5. Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, et al. (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 48:1429–1434

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3